Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Mumps

Treatments: Drug: Botulinum Toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT01390922

114880

Details and patient eligibility

About

The objective of this post-marketing surveillance study is to collect safety, efficacy and usage data on botulinum injection in subjects with upper or lower limb spasticity on the long-term use in clinical practice and to identify the factors affecting the safety or efficacy.

Enrollment: 1,038 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with upper or lower limb spasticity
• Subjects must use botulinum injection for the first time

Exclusion criteria

• Not applicable

Trial design

1,038 participants in 1 patient group

Subjects prescribed botulinum injection

Description:

Subjects prescribed botulinum injection

Treatment:

Drug: Botulinum Toxin Type A